Functional Concept – Page 38

Lilly’s Zepbound Outshines Novo’s Wegovy in First Head-to-Head Weight Loss Study

7 months ago talkbio0Tagged Eli, Eli Lilly, Nordisk, Obesity, SURMOUNT-5, Wegovy, Weight Loss, Zepbound

Eli Lilly, Novo Nordisk, Zepbound, Wegovy, Weight Loss, Obesity Treatment, Head-to-Head Study, SURMOUNT-5

GSK Terminates Development of HBV Therapeutic Vaccine Due to Efficacy Failure

7 months ago talkbio0Tagged Clinical Trial Termination, Effectiveness, Failure (biologic function), Hepatitis B, SmithKline Beecham, Vaccines

GSK, HBV, therapeutic vaccine, efficacy failure, clinical trial termination

Gilead Partners with Tubulis to Revitalize ADC Pipeline

7 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Biotechnology, Gilead Sciences, Immunostimulating conjugate (antigen), Malignant Neoplasms, Partnership, Tubulis

Gilead Sciences, Tubulis, Antibody-Drug Conjugates (ADCs), Cancer Treatment, Biotechnology Partnership

Takeda Acquires Rights to Rival BMS’ Reblozyl with $200M Upfront Payment to Keros

7 months ago talkbio0Tagged Bristol Myers Squibb, Dosage Forms, Malignant Neoplasms, Reblozyl, Takeda

Takeda, Keros Therapeutics, Bristol-Myers Squibb, Reblozyl, Cancer Treatment, Pharmaceutical Deal

Merus’s Petosemtamab Demonstrates Promising Efficacy in Expanded HNSCC Dataset

7 months ago talkbio0Tagged Clinical Trials, Congress (U.S. Legislature), ESMO, Head, Malignant Neoplasms, Merus, MRUS, N.V., Petosemtamab, Squamous cell carcinoma of the head and neck

Petosemtamab, HNSCC (Head and Neck Squamous Cell Carcinoma), Merus N.V. (MRUS), Clinical Trial Results, Cancer Treatment, ESMO Asia Congress 2024

Merck and Kelun-Biotech Advance in Cancer Treatment with Exclusive License Agreement for Investigational ADC Candidates

8 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Immunostimulating conjugate (antigen), Kelun-Biotech, Malignant Neoplasms, Merck, NECTIN4 gene, SKB571, TROP2

Merck, Kelun-Biotech, Antibody-Drug Conjugates (ADC), Cancer Treatment, Exclusive License Agreement, TROP2, Nectin-4, SKB571

European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

8 months ago talkbio0Tagged BeiGene, Cancer Therapeutic Procedure, Commission approval, European (ethnic group), first-line, Gastroesophageal Junction Adenocarcinoma, Squamous cell carcinoma of esophagus, Stomach, Tevimbra, tislelizumab

TEVIMBRA, tislelizumab, European Commission approval, first-line treatment, esophageal squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, cancer treatment, BeiGene.

Acadia Pharmaceuticals Secures Exclusive Licensing Deal for Saniona’s Tremor Treatment Asset Worth Up to $582 Million

8 months ago talkbio0Tagged Acadia, biobucks, nervous system disorder, Saniona, Tremor

Acadia Pharmaceuticals, Saniona, tremor treatment, licensing deal, biobucks, neurological disorder

PTC Therapeutics Sells Priority Review Voucher for $150M Following Phase 2 ALS Trial Failure

8 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, factor IX, Failure (biologic function), Phase 2 trial, Priority Review

PTC Therapeutics, ALS, Phase 2 trial failure, priority review voucher, $150M sale

Embecta Discontinues Insulin Patch Pump Program Amid Restructuring Efforts

8 months ago talkbio0Tagged Diabetes, Discontinuation (procedure), Embecta, insulin patch, pump (device), restructuring, Technology

Embecta, insulin patch pump, discontinuation, restructuring, layoffs, diabetes technology